Athera Biotechnologies AB

August 23, 2011 05:43 ET

Athera Receives Allowance of Key Patent for CVD Antibody Therapy

SOLNA, SWEDEN--(Marketwire - Aug 23, 2011) - Athera Biotechnologies, part of the Karolinska Development portfolio, announced today that the US Patent Office intends to grant a key patent related to the Company's intellectual property covering its therapeutic antibody candidate PC-mAb. Following subsequent grant, the patent will provide strong protection for pharmaceutical uses of PC-mAb for the treatment of atherosclerosis and prevention of ischemic cardiovascular diseases. The corresponding European and Australian patents have already been granted and further applications are pending worldwide.

"This US patent strengthens our efforts in building an attractive and competitive pharmaceutical product portfolio in cardiovascular disease," says Carina Schmidt, Athera Biotechnologies CEO. "I am convinced that PC-mAb has the potential to develop into a medicine that will fulfill important medical needs. We can see this also in a great interest from the pharmaceutical industry to explore partnering opportunities with Athera for future clinical developments."

About Athera Biotechnologies AB (publ)

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach.

PC-mAb from Athera is currently in pre-clinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore cardio-protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome.

In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera's novel therapeutics.

Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio.

Athera Receives Allowance of Key Patent for CVD Antibody Therapy:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Athera Biotechnologies AB via Thomson Reuters ONE


Contact Information

  • For further Information:

    Athera Biotechnologies AB (publ)
    Chief Executive Officer
    Carina Schmidt
    Tel +46 761938190
    Email Contact